|
COPYRIGHT 2005 International Medical News Group
VIENNA -- The endothelin receptor antagonist bosentan, currently used for the treatment of pulmonary hypertension, also is showing long-term beneficial effects on digital ulceration and cutaneous fibrosis in patients with scleroderma.
Short-term improvements on digital ulcers associated with Raynaud's phenomenon in patients with systemic sclerosis have previously been reported, but a group of eight patients with ulcers that have not responded to other treatments--including intravenous iloprost--now have been given oral bosentan for...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
